Caisson Biotech Expands HEPtune Drug Delivery Deal with Novo Nordisk

Caisson Biotech, LLC, a biopharmaceutical company with a patented heparosan-based drug delivery technology, HEPtune, has expanded the scope of its partnership with global healthcare leader Novo Nordisk A/S.

This latest license agreement gives Novo Nordisk 1) exclusive rights to commercialise insulin conjugated to HEPtune and 2) non-exclusive rights to leverage the HEPtune technology across other core therapeutic areas including other diabetes care products, human growth hormone therapy, treatments for obesity and for inflammatory diseases, such as Crohn’s, lupus, rheumatoid and psoriatic arthritis.  

Under the terms of the agreement, Caisson will be eligible to receive up to $167 million in milestone payments upon achievement of certain predefined clinical, regulatory and commercial objectives plus potential long-term residual royalties. 

“Novo Nordisk has completed feasibility studies that pre-clinically validate Caisson’s heparosan-based drug delivery technology for product pharmacokinetics and enhanced half-life,” said Dr Paul DeAngelis, Chief Scientist of Caisson. “The HEPtune technology uses heparosan, a naturally occurring sugar polymer produced by the body that is stable and inert in the bloodstream while being biodegradable. Furthermore, HEPtune can be customised with respect to polymer size and conjugation chemistry thus providing flexibility to enhance a variety of therapeutic proteins and peptides.” 

“As a respected healthcare leader, Novo Nordisk has been an ideal partner and provides the infrastructure and expertise necessary to develop these much-needed therapeutic products,” said Thomas Harlan, CEO of Caisson. “We look forward to our continued collaboration under this new license and to assisting Novo Nordisk in achieving its goal of developing these products and helping more patients.”